Larson Financial Group
STOK icon

Larson Financial Group’s Stoke Therapeutics STOK Stock Holding History

Larson Financial Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.35K Buy
129
+5
+4% +$151 ﹤0.01% 3027
2026
Q2 		$4.06K Buy
124
+7
+6% +$225 ﹤0.01% 2855
2026
Q1 		$3.81K Buy
117
+25
+27% +$820 ﹤0.01% 2726
2025
Q4 		$2.92K Sell
92
-22
-19% -$661 ﹤0.01% 2678
2025
Q3 		$2.68K Buy
114
+92
+418% +$1.58K ﹤0.01% 2591
2025
Q2 		$250 Sell
22
-16
-42% -$152 ﹤0.01% 3022
2025
Q1 		$253 Buy
+38
New +$354 ﹤0.01% 2737

Other funds holding STOK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
SYM Financial Corp
SYM Financial Corp Winona Lake, Indiana $1.31B AUM 18.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Larson Financial Group's STOK Position: Q3 2026 in Review

Larson Financial Group increased its Stoke Therapeutics (STOK) stake by 4% in Q3 2026, buying an estimated $151 and bringing the position to 129 shares worth $3.35K. The position accounts for ﹤0.01% of the portfolio, ranked #3027.

Larson Financial Group first reported a position in STOK in Q1 2025 and has held it in 7 quarters since. The position peaked at $4.06K in Q2 2026. 57 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Larson Financial Group held 129 shares of Stoke Therapeutics worth $3.35K as of Q3 2026.
  • Larson Financial Group bought 5 Stoke Therapeutics shares in Q3 2026, an estimated $151.
  • Stoke Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #3027 holding.
  • Larson Financial Group first reported a position in Stoke Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Larson Financial Group's Stoke Therapeutics position peaked at $4.06K in Q2 2026.
  • 57 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.